Radio-responsive tumors exhibit greater intratumoral immune activity than nonresponsive tumors

International Journal of Cancer

Volumn 134, Issue 10, 2014, Pages 2383-2392

  Gerber, Scott A ^a   Lim, Joanne Y H ^a   Connolly, Kelli A ^a   Sedlacek, Abigail L ^a   Barlow, Margaret L ^a   Murphy, Shawn P ^a   Egilmez, Nejat K ^b   Lord, Edith M ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

cancer radiotherapy; cytotoxic T cells; interferon gamma; interleukin 12; responders

Indexed keywords

CESIUM 137; GAMMA INTERFERON; INTERLEUKIN 12; MICROSPHERE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RADIOTHERAPY; CANCER REGRESSION; CD8+ T LYMPHOCYTE; CLINICAL EFFECTIVENESS; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOLYSIS; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR CELL; TUMOR IMMUNITY;

CANCER RADIOTHERAPY; CYTOTOXIC T CELLS; INTERFERON-GAMMA; INTERLEUKIN-12; RESPONDERS;

ADENOCARCINOMA; ANALYSIS OF VARIANCE; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CHEMORADIOTHERAPY; COLONIC NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; IMMUNE SYSTEM; INTERFERON-GAMMA; INTERLEUKIN-12; MICE; TREATMENT OUTCOME;

EID: 84895919162     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28558     Document Type: Article

References (31)

1. Ogawa K, Murayama S, Mori M,. Predicting the tumor response to radiotherapy using microarray analysis (Review). Oncol Rep 2007; 18: 1243-8.
2. Watanabe T, Komuro Y, Kiyomatsu T, et al. Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy by DNA microarray analysis of gene expression profiles. Cancer Res 2006; 66: 3370-4.
3. Farnebo L, Jerhammar F, Ceder R, et al. Combining factors on protein and gene level to predict radioresponse in head and neck cancer cell lines. J Oral Pathol Med 2011; 40: 739-46.
4. Farnebo L, Tiefenbock K, Ansell A, et al. Strong expression of survivin is associated with positive response to radiotherapy and improved overall survival in head and neck squamous cell carcinoma patients. Int J Cancer 2013; 133: 1994-2003.
5. Kurt A, Yanar F, Asoglu O, et al. Low Mmp 9 and VEGF levels predict good oncologic outcome in mid and low rectal cancer patients with neoadjuvant chemoradiation. BMC Clin Pathol 2012; 12: 27.
6. Sobajima J, Kumamoto K, Haga N, et al. Early evaluation of the apoptotic index ratio is useful in predicting the efficacy of chemoradiotherapy in esophageal squamous cell carcinoma. Oncol Lett 2012; 3: 287-92.
7. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-60.
8. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-9.
9. Gerber SA, Sedlacek AL, Cron KR, et al. IFN-gamma mediates the antitumor effects of radiation therapy in a murine colon tumor. Am J Pathol 2013; 182: 2345-54.
10. Lee Y, Auh SL, Wang Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 2009; 114: 589-95.
11. Liang H, Deng L, Chmura S, et al. Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing. J Immunol 2013; 190: 5874-81.
12. Lugade AA, Moran JP, Gerber SA, et al. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 2005; 174: 7516-23.
13. Lugade AA, Sorensen EW, Gerber SA, et al. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol 2008; 180: 3132-9.
14. Meng Y, Beckett MA, Liang H, et al. Blockade of tumor necrosis factor alpha signaling in tumor-associated macrophages as a radiosensitizing strategy. Cancer Res 2010; 70: 1534-43.
15. Takeshima T, Chamoto K, Wakita D, et al. Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. Cancer Res 2010; 70: 2697-706.
16. Vignali DA, Kuchroo VK,. IL-12 family cytokines: immunological playmakers. Nat Immunol 2012; 13: 722-8.
17. Trinchieri G, Scott P,. Interleukin-12: basic principles and clinical applications. Curr Top Microbiol Immunol 1999; 238: 57-78.
18. Corbett TH, Griswold DP, Jr, Roberts BJ, et al. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res 1975; 35: 2434-9.
19. Gerber SA, Moran JP, Frelinger JG, et al. Mechanism of IL-12 mediated alterations in tumour blood vessel morphology: analysis using whole-tissue mounts. Br J Cancer 2003; 88: 1453-61.
20. Egilmez NK, Jong YS, Mathiowitz E, et al. Tumor vaccination with cytokine-encapsulated microspheres. Methods Mol Med 2003; 75: 687-96.
21. Kilinc MO, Aulakh KS, Nair RE, et al. Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors. J Immunol 2006; 177: 6962-73.
22. Egilmez NK, Jong YS, Sabel MS, et al. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. Cancer Res 2000; 60: 3832-7.
23. Harden JL, Gu T, Kilinc MO, et al. Dichotomous effects of IFN-gamma on dendritic cell function determine the extent of IL-12-driven antitumor T cell immunity. J Immunol 2011; 187: 126-32.
24. McBride WH, Chiang CS, Olson JL, et al. A sense of danger from radiation. Radiat Res 2004; 162: 1-19.
25. Meijer TW, Kaanders JH, Span PN, et al. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res 2012; 18: 5585-94.
26. Horsman MR, Mortensen LS, Petersen JB, et al. Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol 2012; 9: 674-87.
27. Sovik A, Malinen E, Bruland OS, et al. Optimization of tumour control probability in hypoxic tumours by radiation dose redistribution: a modelling study. Phys Med Biol 2007; 52: 499-513.
28. Sedlacek AL, Gerber SA, Randall TD, et al. Generation of a dual-functioning antitumor immune response in the peritoneal cavity. Am J Pathol 2013; 183: 1318-28.
29. Gee K, Guzzo C, Che Mat NF, et al. The IL-12 family of cytokines in infection, inflammation and autoimmune disorders. Inflamm Allergy Drug Targets 2009; 8: 40-52.
30. Del Vecchio M, Bajetta E, Canova S, et al. Interleukin-12: biological properties and clinical application. Clin Cancer Res 2007; 13: 4677-85.
31. Belka C, Marini P, Budach W, et al. Radiation-induced apoptosis in human lymphocytes and lymphoma cells critically relies on the up-regulation of CD95/Fas/APO-1 ligand. Radiat Res 1998; 149: 588-95.